CIBC Bancorp USA’s Inovio Pharmaceuticals INO Stock Holding History

CIBC Bancorp USA’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$87K	–	1991
2026 Q1	$87K	Buy	+50,000	New	+$82.3K	﹤0.01%	1690

Other funds holding INO

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CIBC Bancorp USA's INO Position: Q2 2026 in Review

CIBC Bancorp USA sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 50,000 shares — an estimated $87K sold.

CIBC Bancorp USA first reported a position in INO in Q1 2026 and held it in 1 quarter. The position peaked at $87K in Q1 2026. 102 funds tracked by Wall St. Rank hold INO as of Q2 2026.

CIBC Bancorp USA reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
CIBC Bancorp USA sold 50,000 Inovio Pharmaceuticals shares in Q2 2026, an estimated $87K.
CIBC Bancorp USA first reported a position in Inovio Pharmaceuticals in Q1 2026 and held it in 1 quarter.
CIBC Bancorp USA's Inovio Pharmaceuticals position peaked at $87K in Q1 2026.
102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.